Biodexa Pharmaceuticals Plc (BDRX)Healthcare | Biotechnology | Cardiff, United Kingdom | NasdaqCM
3.48 USD
+0.01
(0.288%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.49 +0.01 (0.342%) ⇧ (April 17, 2026, 7:44 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:38 p.m. EDT
Sell immediately and never add; the stock is in a bearish death spiral triggered by a failed $10M equity raise, marked down from a $96.50 high to ~$3.50, with the forecasting model predicting a catastrophic 33% further decline in the next 45 days and showing strong statistical evidence (H-stat > 4, extreme Ljung-Box rejection) that the current downtrend is highly persistent, while the company remains unprofitable with deep burning cash flow. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.326895 |
| AutoARIMA | 0.740022 |
| AutoETS | 0.745050 |
| MSTL | 0.749847 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 4.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.149 |
| Excess Kurtosis | -0.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.535 |
| Market Cap | 2,256,132 |
| Forward P/E | Infinity |
| Beta | 1.11 |
| Previous Name | Midatech Pharma plc |
| Website | https://www.biodexapharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.94956523 |
| Address1 | 1 Caspian Point |
| Address2 | Caspian Way |
| All Time High | 809,000,000.0 |
| All Time Low | 2.86 |
| Ask | 3.54 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 191,080 |
| Average Daily Volume3 Month | 464,646 |
| Average Volume | 464,646 |
| Average Volume10Days | 191,080 |
| Beta | 1.11 |
| Bid | 3.37 |
| Bid Size | 1 |
| Book Value | 34.273876 |
| City | Cardiff |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.48 |
| Current Ratio | 2.03 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.56 |
| Day Low | 3.4 |
| Debt To Equity | 0.535 |
| Display Name | Biodexa Pharmaceuticals |
| Dividend Date | 1,583,193,600 |
| Ebitda | -8,593,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -131,276.38 |
| Enterprise Value | 1,128,057,929,728 |
| Eps Current Year | 0.0 |
| Eps Forward | 0.0 |
| Eps Trailing Twelve Months | -3.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.5012 |
| Fifty Day Average Change | -1.0212002 |
| Fifty Day Average Change Percent | -0.22687286 |
| Fifty Two Week Change Percent | -94.95652 |
| Fifty Two Week High | 96.5 |
| Fifty Two Week High Change | -93.02 |
| Fifty Two Week High Change Percent | -0.96393776 |
| Fifty Two Week Low | 2.86 |
| Fifty Two Week Low Change | 0.6200001 |
| Fifty Two Week Low Change Percent | 0.21678327 |
| Fifty Two Week Range | 2.86 - 96.5 |
| Financial Currency | GBP |
| First Trade Date Milliseconds | 1,449,498,600,000 |
| Float Shares | 274,937,001,120 |
| Forward Eps | 0.0 |
| Forward P E | Infinity |
| Free Cashflow | -1,003,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -3,961,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00075 |
| Held Percent Institutions | 0.10318 |
| Implied Shares Outstanding | 648,314 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,775,433,600 |
| Last Split Factor | 1:5 |
| Long Business Summary | Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom. |
| Long Name | Biodexa Pharmaceuticals Plc |
| Market | us_market |
| Market Cap | 2,256,132 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_278298574 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -6,384,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,256,130 |
| Number Of Analyst Opinions | 1 |
| Open | 3.42 |
| Operating Cashflow | -5,591,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 44 29 2048 0180 |
| Post Market Change | 0.011899948 |
| Post Market Change Percent | 0.34195253 |
| Post Market Price | 3.4919 |
| Post Market Time | 1,776,469,496 |
| Prev Name | Midatech Pharma plc |
| Previous Close | 3.47 |
| Price Hint | 4 |
| Price To Book | 0.10153506 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.429 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.288184 |
| Regular Market Day High | 3.56 |
| Regular Market Day Low | 3.4 |
| Regular Market Day Range | 3.4 - 3.56 |
| Regular Market Open | 3.42 |
| Regular Market Previous Close | 3.47 |
| Regular Market Price | 3.48 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 14,380 |
| Return On Assets | -0.32786998 |
| Return On Equity | -0.64722997 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 648,314 |
| Shares Percent Shares Out | 0.0023 |
| Shares Short | 1,506 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,483 |
| Short Name | Biodexa Pharmaceuticals plc |
| Short Percent Of Float | 0.0023 |
| Short Ratio | 0.1 |
| Source Interval | 15 |
| Symbol | BDRX |
| Target High Price | 35.872963 |
| Target Low Price | 35.872963 |
| Target Mean Price | 35.872963 |
| Target Median Price | 35.872963 |
| Total Cash | 8,534,000 |
| Total Cash Per Share | 0.0 |
| Total Debt | 61,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.722324 |
| Two Hundred Day Average Change | -19.242325 |
| Two Hundred Day Average Change Percent | -0.8468467 |
| Type Disp | Equity |
| Volume | 14,380 |
| Website | https://www.biodexapharma.com |
| Zip | CF10 4DQ |